Evidence map›Paper›PMID 34452251›Full record

ReviewPharmaceutics2021

Polymeric Lipid Hybrid Nanoparticles (PLNs) as Emerging Drug Delivery Platform-A Comprehensive Review of Their Properties, Preparation Methods, and Therapeutic Applications.

Durgaramani Sivadasan, Muhammad Hadi Sultan, Osama Madkhali, Yosif Almoshari, Neelaveni Thangavel

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Advances in Drug Delivery Systems for Boswellic Acids fromInternational journal of molecular sciences · 2026
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Applications of Nanobiotechnology in Medicine.Life (Basel, Switzerland) · 2026
    Review
  17. Review
  18. Review
  19. Review
  20. Review

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Durgaramani SivadasanDepartment of Pharmaceutics, College of Pharmacy, Jazan University, Jazan 114, Saudi Arabia.ORCID 0000-0002-9174-8406
Muhammad Hadi SultanDepartment of Pharmaceutics, College of Pharmacy, Jazan University, Jazan 114, Saudi Arabia.
Osama MadkhaliDepartment of Pharmaceutics, College of Pharmacy, Jazan University, Jazan 114, Saudi Arabia.ORCID 0000-0001-5139-8408
Yosif AlmoshariDepartment of Pharmaceutics, College of Pharmacy, Jazan University, Jazan 114, Saudi Arabia.
Neelaveni ThangavelDepartment of Pharmaceutical Chemistry, Jazan University, Jazan 114, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polymeric lipid hybrid nanoparticles (PLNs) are core-shell nanoparticles made up of a polymeric kernel and lipid/lipid-PEG shells that have the physical stability and biocompatibility of both polymeric nanoparticles and liposomes. PLNs have emerged as a highly potent and promising nanocarrier for a variety of biomedical uses, including drug delivery and biomedical imaging, owing to recent developments in nanomedicine. In contrast with other forms of drug delivery systems, PLNs have been regarded as seamless and stable because they are simple to prepare and exhibit excellent stability. Natural, semi-synthetic, and synthetic polymers have been used to make these nanocarriers. Due to their small scale, PLNs can be used in a number of applications, including anticancer therapy, gene delivery, vaccine delivery, and bioimaging. These nanoparticles are also self-assembled in a reproducible and predictable manner using a single or two-step nanoprecipitation process, making them significantly scalable. All of these positive attributes therefore make PLNs an attractive nanocarrier to study. This review delves into the fundamentals and applications of PLNs as well as their formulation parameters, several drug delivery strategies, and recent advancements in clinical trials, giving a comprehensive insight into the pharmacokinetic and biopharmaceutical aspects of these hybrid nanoparticles.

Indexed as

drug delivery mechanismshigh-pressure homogenizationnanomedicinepolymeric lipid nanoparticlesquality by design approach

Identifiers

PMID34452251
PMCPMC8399620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.